middle.news
Argent BioPharma Cuts Costs, Posts Positive CimetrA® Trial, and Secures EU Drug Approvals
9:42am on Wednesday 30th of April, 2025 AEST
•
Healthcare
Read Story
Argent BioPharma Cuts Costs, Posts Positive CimetrA® Trial, and Secures EU Drug Approvals
9:42am on Wednesday 30th of April, 2025 AEST
Key Points
Over USD $1 million annual savings by outsourcing EU GMP-certified production
Phase IIb trial confirms CimetrA®’s safety and anti-inflammatory potential
CogniCann™ receives German prescription approval and first commercial orders
CannEpil™ approved for prescription in Germany, expanding European footprint
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Argent Biopharma (ASX:RGT)
OPEN ARTICLE